| Change from baseline | Posterior quantities* |
---|
Treatment group | Total N | Mean | SD | Pr (Max) | Pr (ED90) | Pr Superiority | Pr (CSD) |
---|
ADCOMS—overall |
Placebo control | 229 | 0.113 | 0.012 | – | – | – | – |
2.5 mg/kg biweekly | 51 | 0.134 | 0.024 | 0.009 | 0.009 | 0.216 | 0.028 |
5 mg/kg monthly | 48 | 0.119 | 0.021 | 0.022 | 0.031 | 0.416 | 0.070 |
5 mg/kg biweekly | 87 | 0.116 | 0.016 | 0.010 | 0.010 | 0.446 | 0.053 |
10 mg/kg monthly | 242 | 0.084 | 0.011 | 0.318 | 0.386 | 0.961 | 0.479 |
10 mg/kg biweekly | 143 | 0.077 | 0.014 | 0.642 | 0.563 | 0.976 | 0.638 |
- Only subjects with non-missing data at both baseline and the relevant post-baseline visit are included in the change from baseline summary statistics
- ADCOMS, Alzheimer’s Disease Composite Score; CSD, clinically significant difference; 25% better than placebo, ED90, dose regimen with at least 90% of the dmax treatment effect; Max, maximum treatment effect; Pr, probability; Pr (Max), probability of being maximal effective dose; Pr (ED90), probability of being the ED90 dose; Pr (Superiority), probability to be superior to placebo by any magnitude; Pr (CSD), probability to be better than placebo by at least 25%
- *Probabilities can be interpreted as a percentage (e.g., 0.10 is 10%)